#USA #California #Terumo Neuro #SOFIA Flow 88 #Neurovascular

New Data on SOFIA Flow 88's Performance in the EMEA Region

Introduction

Terumo Neuro, a global leader in neurovascular innovation and a subsidiary of Terumo Corporation, has recently introduced compelling new data at the 17th Annual Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT). This data reveals strong preferences among EMEA physicians for the SOFIA Flow 88 neurovascular aspiration catheter. These insights mark the first public presentation of studies comparing the catheter's performance against other solutions in key metrics such as navigation, tractability, and overall user experience.

Key Findings

The study, which spanned 70 procedures across 16 hospitals in the EMEA region and involved 31 physicians, yielded notable results:

• - An impressive 83% of physicians reported that the SOFIA Flow 88 reliably reached target sites, even in anatomically complex cases.
• - 100% of doctors perceived the SOFIA Flow 88 as either “identical” or “better” when compared to the SOFIA Plus 6F in terms of locating target vessel placements.
• - A high 92% of physicians rated the SOFIA Flow 88 as “identical,” “better,” or “much better” than other general aspiration catheters.

Dr. Carsten Schroeder, President and CEO of Terumo Neuro, commented, "The SOFIA Flow 88 aspiration catheter is a significant advancement in the treatment of mechanical thrombectomy in the EMEA region. Its design maximizes aspiration while minimizing flow disturbance and providing exceptional support, allowing physicians to navigate tortuous anatomies with minimal trauma. The physician preference data clearly underscores the excellent performance of the SOFIA Flow 88 catheter. This data further solidifies the SOFIA catheter line's reputation as a 'best-in-class' solution for tractability, navigation, and overall performance."

Design Features

Released in the EMEA region on June 2, 2025, the SOFIA Flow 88 is engineered for optimal tractability, proximal stability, and flexibility tailored to vascular needs. Its design is intended to enhance control for physicians and seamlessly integrate into a variety of aspiration and combination strategies.

This appeal is particularly underscored by findings from the American SOFAST study and the European SESAME study, which confirmed the safety and efficacy of the SOFIA catheter as a first-line solution in mechanical thrombectomy procedures. Furthermore, the SOFIA Flow 88 is compatible with the SOFIA Plus 6F aspiration catheter, contributing to Terumo Neuro's comprehensive solution for stroke treatment that includes:

• - The ERIC™ recovery device, allowing for thrombus control and procedural versatility.
• - The BOBBY™ balloon guide catheter, offering reliable flow cessation with next-generation balloon technology.
• - The WEDGE™ and HEADWAY™ microcatheters, designed for enhanced navigation and access efficiency.
• - The TRAXCESS™ guidewires, featuring a soft tip ideal for challenging anatomies.

Conclusion

Terumo Neuro's commitment to redefining possibilities in neurovascular treatment is evident through its innovative product lineup, especially the SOFIA Flow 88 catheter. Established in 1997 as MicroVention, Terumo Neuro has grown its repertoire to include over thirty products aimed at treating cerebral aneurysms, ischemic strokes, carotid artery diseases, and neurovascular malformations. Based in California, the company boasts operations in over seventy countries, supported by strategic distribution partnerships and manufacturing sites in California and Costa Rica.

For more information on Terumo Neuro and its offerings, visit www.terumoneuro.com.